创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology iHuPDX Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-14 15:11
  • Views:

(Summary description)In the field of biomedicine, innovation is an important driving force for technological advancement and clinical application. With its iHuPDX (Individualized Human Patient-Derived Xenograft) platform, InnoModels Biotechnology (Beijing) Co., Ltd. is bringing unprecedented changes to cancer research and treatment. This platform not only demonstrates InnoModels' profound strength in the field of personalized medicine, but also provides new hope and possibilities for tumor treatment.

InnoModels Biotechnology iHuPDX Platform

(Summary description)In the field of biomedicine, innovation is an important driving force for technological advancement and clinical application. With its iHuPDX (Individualized Human Patient-Derived Xenograft) platform, InnoModels Biotechnology (Beijing) Co., Ltd. is bringing unprecedented changes to cancer research and treatment. This platform not only demonstrates InnoModels' profound strength in the field of personalized medicine, but also provides new hope and possibilities for tumor treatment.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-14 15:11
  • Views:
Information

In the field of biomedicine, innovation is an important driving force for technological advancement and clinical application. With its iHuPDX (Individualized Human Patient-Derived Xenograft) platform, InnoModels Biotechnology (Beijing) Co., Ltd. is bringing unprecedented changes to cancer research and treatment. This platform not only demonstrates InnoModels' profound strength in the field of personalized medicine, but also provides new hope and possibilities for tumor treatment.
Core Advantages of iHuPDX Technology
iHuPDX technology is a xenotransplantation technology based on individual patient's tumor cells, the core of which lies in the establishment of a tumor model that is highly close to the actual situation of the patient. Cancer tissue samples are collected from patients and transplanted into animals such as mice to form individualized transplanted tumors. This highly individualized disease model can not only more accurately simulate the biological characteristics of the patient's tumor growth, metastasis, and drug response, but also provide doctors with an important basis for a comprehensive understanding of the patient's tumor characteristics.
Strong support for precision medicine
Traditional tumor models are often based on standardized cell lines or tissue samples, which cannot fully reflect the uniqueness of a patient's tumor. The iHuPDX platform, on the other hand, is derived directly from the patient's tumor cells, and is therefore able to more accurately simulate the actual condition of the patient's tumor. This technology provides an important basis for the development of personalized treatment plans, enabling physicians to select the most appropriate drug combinations and dosages for patients prior to treatment, thereby increasing the success rate of treatment and reducing unnecessary risks.

 


Accuracy of Drug Response Prediction
The iHuPDX platform also has significant advantages in drug response prediction. Due to the high degree of similarity between the model and the patient's tumor, researchers can test the response of different drugs on the model against a specific patient's tumor, thereby predicting the drug's efficacy and possible side effects in the patient. This predictive ability provides physicians with important decision support, allowing for more scientific and precise treatment planning.
Stability and Growth Rate of the Technology
The iHuPDX platform also excels in technology stability and growth rate. With advanced primary cell inoculation technology, the model is able to achieve early and uniform growth, ensuring that efficacy experiments are conducted within the optimal window. At the same time, the homogenization of the same batch of samples is ensured through the modeling of cell suspensions, resulting in a high degree of consistency in the growth rate and biological characteristics of the models. This stability not only ensures the reliability of experimental results, but also reduces experimental and time costs.
New breakthrough in tumor immunity research
InnoModels Biotechnology also combined the iHuPDX platform with the humanized model of the PBMC immune system, providing a more ideal model for tumor immunity research. This combination enables the model to simulate not only tumor growth and drug response, but also the interaction between the tumor and the immune system. This provides a powerful tool for a deeper understanding of tumor immune mechanisms and the development of new immunotherapies, driving further development in the field of tumor therapy.
Future Prospects of InnoModels Biotechnology
InnoModels Biotechnology (Beijing) Co., Ltd. is confident in the future of the iHuPDX platform. With the deepening of biomedical research and continuous technological innovation, iHuPDX platform is expected to play a more important role in the field of personalized medicine. In the future, we can expect to see more research results and application scenarios related to iHuPDX technology, which will bring more accurate and effective treatment solutions to patients.
Since its establishment, InnoModels Biotechnology has been committed to promoting innovation in the field of biomedicine and has established several unique modeling platforms, including the iHuPDX platform. The Company has not only made remarkable achievements in the field of new drug development, but also helped the industry develop at a rapid pace by providing the most clinically referenced preclinical research support to innovators in oncology and tumor immunotherapy.
In summary, with its high degree of individualization, accurate drug response prediction and stable and reliable growth characteristics, the iHuPDX platform of InnoModels Biotechnology has become an important support for personalized precision medicine. In the future, with the continuous development and improvement of the technology, iHuPDX platform will play an even more important role in the field of cancer treatment, bringing hope and gospel to more patients.   

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司